Musings on the current state of COVID-19 modeling and reporting Peter L. Bonate Editorial 29 May 2020 Pages: 183 - 185
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome Malek OkourMahmoud Al-KofahiDaren Austin Commentary 13 May 2020 Pages: 187 - 188
Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2 Roberto GomeniTianhong XuFrançoise Bressolle-Gomeni Original Paper Open access 20 May 2020 Pages: 189 - 198
Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy Anil R. MaharajHuali WuMichael Cohen-Wolkowiez Original Paper 22 April 2020 Pages: 199 - 218
Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique Astrid BroekerSebastian G. Wicha Original Paper Open access 04 April 2020 Pages: 219 - 228
Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling Michiel J. van EsdonkJacobus BurggraafJasper Stevens Original Paper Open access 04 April 2020 Pages: 229 - 239
A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autism Elham HaemMarziyeh DoostfatemehMats O. Karlsson Original Paper 13 April 2020 Pages: 241 - 253
A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus Sonja HartmannKonstantinos BiliourisMirjam N. Trame Original Paper 25 April 2020 Pages: 255 - 266